Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Pelthos Therapeutics Inc (PTHS)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$10.15-5.84%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PTHS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage ongoing litigation and regulatory challenges | A primary condition in Pelthos Therapeutics Inc's published investment case. The stated target is No new major litigation filings and resolution of existing cases by end of 2026. | Intact | New significant litigation filings or regulatory penalties occur after mid-2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making commercialization story, not an established compounder. The long-term thesis is in a watch state, with low overall confidence after recent financial performance lagged its industry cohort.
The evidence gives no valuation multiple or clear account of market expectations, so whether PTHS is cheap or expensive versus peers cannot be assessed. No pricing fragility signals were flagged, but that does not resolve the valuation uncertainty.
Near term, earnings risk is elevated because PTHS missed its latest quarter, and the evidence points to a meaningful chance of another miss. Zelsuvmi revenue and dispensed units grew from Q1 to Q2, while evidence for the planned 2027 Xepi and Xeglyze launches remains limited. Cash fell from $32.0 million at Q1 end to $24.2 million at Q2 end, despite management saying the Q2 balance was expected to support the current plan.
The multi-year view hinges on continued Zelsuvmi growth, progress toward the Xepi and Xeglyze plans, and maintaining enough financial flexibility to execute. Near-term guidance cuts or further labor-market weakening would add pressure; continued strength from healthcare sector bellwethers could support the sector backdrop. The recent FDA approval is positive, but the supplied evidence does not detail its commercial impact.
Over the next 1 to 3 years, PTHS combines a real early commercial gain and a favorable sector backdrop with weak performance, losses, and high execution and financing risk. Evidence remains thin, so the thesis depends on sustained product progress and clearer financial delivery. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company recently promoted a new CFO to stabilize leadership. |
| Intact |
| Additional key executive departures or leadership turmoil occur in FY26 |
0 executive departures vs 0 target CEO employment amendment confirms stability; no departures or turmoil detected in recent news or filings. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Growth of ZELSUVMI product sales | Pelthos aims to grow sales of its ZELSUVMI product, which management prioritizes. | Broken | revenue falls below $7 million in FY25 or fails to grow toward $121 million by FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.67 → $-4.21 · observed estimates
$0.12B → $0.11B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-25 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-26 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-27 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-28 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-29 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-30 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-07-31 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-01 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-02 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-03 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-04 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-05 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-06 | $-2.13 | $121,180,000 | 4 / 6 |
| 2026-08-07 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-08 | $-2.13 | $121,180,000 | 4 / 6 |
| 2026-08-09 | $-2.13 | $121,180,000 | 4 / 6 |
| 2026-08-10 | $-2.13 | $121,180,000 | 4 / 6 |
| 2026-08-12 | $-2.13 | $121,180,000 | 4 / 6 |
| 2026-08-13 | $-2.13 | $121,180,000 | 4 / 6 |
| 2026-08-14 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-15 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-16 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-17 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-18 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-19 | $-1.67 | $120,246,667 | 4 / 5 |
| 2026-08-20 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-21 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-22 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-23 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-24 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-25 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-26 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-27 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-28 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-29 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-30 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-08-31 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-01 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-02 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-03 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-04 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-05 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-06 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-07 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-08 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-09 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-10 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-11 | $-3.90 | $112,217,286 | 5 / 6 |
| 2026-09-12 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-13 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-14 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-15 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-16 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-17 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-18 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-19 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-20 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-21 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-22 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-23 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-24 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-25 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-26 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-27 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-28 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-29 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-09-30 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-01 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-02 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-03 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-04 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-05 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-06 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-07 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-08 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-09 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-10 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-11 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-12 | $-3.90 | $112,218,000 | 5 / 6 |
| 2026-10-13 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-14 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-15 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-16 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-17 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-18 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-19 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-20 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-21 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-22 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-23 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-24 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-25 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-26 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-27 | $-4.23 | $110,303,714 | 5 / 6 |
| 2026-10-28 | $-4.33 | $108,395,143 | 5 / 6 |
| 2026-10-29 | $-4.33 | $108,395,143 | 5 / 6 |
| 2026-10-30 | $-4.33 | $108,395,143 | 5 / 6 |
| 2026-10-31 | $-4.33 | $108,166,571 | 5 / 6 |
| 2026-11-01 | $-4.33 | $108,166,571 | 5 / 6 |
| 2026-11-02 | $-4.33 | $108,166,571 | 5 / 6 |
| 2026-11-03 | $-4.33 | $108,166,571 | 5 / 6 |
| 2026-11-04 | $-4.21 | $108,166,571 | 5 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.